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Abstract
White-tailed deer (n = 14 treated, n = 7 control) were examined postmortem to identify any possible pathophysiology resulting from PZP
immunocontraception vaccination. Deer were treated twice in 1997; given a booster in 1998, with six being revaccinated in September 2000.
Granulomas were found at injection sites of most deer, even 2 years post-treatment. Eosinophilic oophoritis occurred in 6 of 8 (75%) deer
vaccinated in 1998, and 3 of 6 (50%) revaccinated in 2000. The 2000 revaccinates without oophoritis, had significantly fewer normal secondary
follicles than control females (P = 0.03), and deer in the1998 treatment group (P = 0.04). PZP immunocontraceptive vaccine elicited ovarian
pathologies in deer similar to those observed in other species.
© 2007 Elsevier Ltd. All rights reserved.
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1. Introduction
Porcine zona pellucida (PZP) antigen has been the most
commonly used immunocontraceptive agent for fertility con-
trol in female mammals [1,2] and has been administered to
112 species of wildlife, including many ungulate species
[3]. Previous investigators have reported the success and
reversibility of PZP vaccination with minimal effect on the
health of white-tailed deer (Odocoileus virginianus) [4–6].
Similarly, Curtis et al. [7] were successful in reducing fawn
production of white-tailed deer after treatment with PZP
immunocontraceptive vaccine.
Kirkpatrick and Rutberg [8] stated that, “the absence of
significant health side effects” is an important characteristic
of any contraceptive vaccine. Concerns about ovarian mal-
function in early PZP trials on other species [9–14] prompted
McShea et al. [4] to conduct histological examinations of
∗ Corresponding author. Tel.: +1 607 255 2835; fax: +1 607 255 2815.
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ovaries from PZP-vaccinated white-tailed deer, and Miller
et al. [15] to monitor progesterone levels throughout their
study. No significant ovarian abnormalities were reported for
treated deer that recovered to normal fertility. Since that time,
a study was conducted on domestic sheep (Ovis aries), a
cervid species that demonstrated marked changes in estrous
cycling and hormone levels associated with severely patho-
logic ovaries [16]. Species- and breed-specific responses to
PZP vaccinations vary both in successful fertility control, and
in pathologic symptoms [10,12,13,16–20]. Consequently, we
present information that is important for evaluation of poten-
tial animal health issues associated with the use of PZP
contraceptive vaccines on white-tailed deer.
We conducted detailed necropsy of white-tailed deer to
examine potential pathological impacts resulting from a suc-
cessful immunocontraceptive vaccination regimen [7]. The
deer we examined were still under the influence of PZP treat-
ment, had detectable levels of PZP antibodies, and many had
not demonstrated full recovery to normal fertility. Patholog-
ical effects of PZP treatment 2 years post-vaccination were
0264-410X/$ – see front matter © 2007 Elsevier Ltd. All rights reserved.
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compared to a sub-sample of deer revaccinated within one
month of necropsy, and untreated deer. Our objectives were
to document ovarian abnormalities or other potential health
concerns resulting from the Curtis et al. [7] PZP vaccination
protocol compared to control deer.
2. Materials and methods
Postmortem examinations were performed promptly on
a sample of white-tailed deer in accordance with a protocol
(No. 96-10-99) amendment approved by the Cornell Uni-
versity Institutional Animal Care and Use Committee. The
deer had been injected with a porcine zona pellucida vaccine
(PZP, n = 14), or left untreated (controls; n = 7) during the
period 1997–2000 as a part of a fertility control study con-
ducted on free-ranging deer contained in a 263-ha fenced,
natural area at Seneca Army Depot near Romulus, New York
[7].
2.1. Vaccine formulation
Female deer were immunized with native porcine zona
pellucida prepared by and purchased from B. Dunbar (Baylor
College of Medicine, Houston, TX) [20–22]. A 1-cc prime
dose of PZP vaccine consisted of 0.5 cc saline containing
100g PZP mixed with 0.5 cc Complete Freund’s Adjuvant
(CFA). Similarly, the 1-cc booster dose contained 100g PZP
in 0.5 cc saline, mixed with Incomplete Freund’s Adjuvant
(IFA) at a 1:1 ratio [5,15].
2.2. Vaccination protocol
The primary vaccination (PZP + CFA) was injected by
hand into the hip region of female deer during winter 1997
as they were captured for recruitment into the study. At the
time of capture, deer were marked with numbered ear tags
and neck collars. Age was determined by the extent of tooth
wear [23], and deer were released into the fenced study area.
The first booster shot (PZP + IFA) was administered remotely
via dart rifle with self-injecting 1-cc darts (Pneu Dart Inc.,
Williamsport, PA) prior to breeding season, 5–7 months later
in September 1997. A second booster treatment (PZP + IFA)
was delivered via dart rifle in September and October 1998.
Booster treatments were suspended until September 2000
when six female deer were revaccinated (PZP + IFA) to pro-
vide the comparison of recently-vaccinated deer to those
previously treated 2 years earlier.
2.3. Deer collection and gross necropsies
In October 2000, within permit authority from the
New York State Department of Environmental Conserva-
tion (NYSDEC), deer were humanely killed by a shot to the
head or neck from a high-powered rifle fired from a blind
or a vehicle [24]. Blood samples were immediately collected
via heart puncture at the time of death and were stored in
vials on ice for transport. Deer (n = 21) were quickly trans-
ported within 2 h after collection to the Cornell University
College of Veterinary Medicine and placed in a cooler at
4.4 ◦C. Most necropsies were performed the day the deer
were collected. Gross examinations included evaluation of
body condition and bone marrow fat [25], examination of
injection sites, and documentation of any visible abnormal-
ities. Ovaries, internal iliac lymph node, popliteal lymph
node, and thyroid glands were stripped of fat and connective
tissue then weighed immediately (nearest mg). Histologi-
cal analysis was performed on tissues fixed in formalin,
embedded in paraffin, cut to 7 thickness, and stained with
hemotoxylin and eosin, Masson’s Trichrome, or acid fast
stains.
2.4. Serology
Blood chemistry analysis was performed by the Cornell
University College of Veterinary Medicine, Animal Health
Diagnostic Center on all of the collected deer. Anti-PZP titers
(titer−1 × 1000) titers were determined via an enzyme-linked
immunosorbent assay (ELISA) as described by Miller et al.
[15] and were compared to ovarian weights and histology.
2.5. Follicle classification
Each ovary was halved before fixation in formalin, and
each half was embedded in paraffin. Multiple sections (but
not step sections) were made of each surface to be examined
with several stains, and if a suspected lesion was observed
grossly, a section was also made through the lesion. The total
number of secondary and Graafian follicles were enumerated
from two cross-sectional slices from each ovary from each
deer. Follicles with greater than 10% apoptotic granulosa
cells were classified as atretic. Apoptosis was characterized
as granulosa cells with dark, small consolidated (hyperchro-
matic) nuclei with an absence of heterochromatin. Likewise,
any normal appearing follicle having the presence of a corona
radiata or total follicular size greater than 0.5 cm was classi-
fied as a Graafian follicle.
A single layer of cuboidal epithelia lined several large fluid
filled follicles. Because none of these follicles exceeded 1 cm
in diameter, they were classified as atretic Graafian follicles;
however, they could have been small follicular cysts. Some
larger Graafian follicles with diminished numbers of granu-
losa cells may have also been early follicular cysts. However,
we found no advanced cyst to confirm this.
3. Results
3.1. Average age when euthanized
At the time of necropsy, the mean age for control deer
was 5.5 years. The 1998 treatment group also had a mean
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age of 5.5 years, and the deer revaccinated in 2000 aver-
aged 6.5 years old. The age differences were not significant
(F2,18 = 1.90, P = 0.18).
3.2. Body condition and fat reserves
On the basis of body weight, external visibility of indi-
vidual rib bones, and subcutaneous fat observed during gross
necropsy, most animals were judged in good to excellent con-
dition and had 85% or more bone marrow fat. However, there
were three exceptions. Deer number 188 (1998 PZP vacci-
nate) had very good teeth and plenty of rumen ingesta, but
she exhibited classic signs of malnutrition normally seen in
deer struggling through an extremely harsh winter (poor body
condition, <50% fat score, and a gelatinous bone marrow).
The other deer with depleted bone marrow fat, number 146
(1998 PZP treatment), and number 323 (control female), had
good to excellent body condition.
3.3. Injection sites
Injection sites for 2000 revaccinates were compared to
those for 1998 vaccinates to evaluate the persistence of dart-
site lesions. While abscesses were more evident and larger in
2000 revaccinates, granulomas could be found at the injection
site of nearly all treated deer.
3.4. Lactation
Five of seven (71%) control females, and five of eight
deer (63%) receiving their last vaccination in 1998 showed
evidence of lactation during summer 2000 prior to the col-
lection. Three of the five (60%) lactating does were also
later identified as having eosinophilic oophoritis. None of
the 2000 revaccinates showed evidence of lactation during
necropsies.
3.5. Blood chemistry
There were few differences in blood chemistry between
control and PZP-treated females (Table 1). Some variation
occurred for selected blood parameters. However, these val-
ues fell within normal ranges and were unremarkable. There
were significantly different titer levels between the groups
(F2,17 = 42.32, P≤ 0.0001) with the highest titers in the 2000
revaccinates (Table 2).
3.6. Ovarian weights
There were also no significant differences in ovarian
weights between controls, 1998 vaccinates, or 2000 revac-
cinates (left, F3,17 = 0.53, P = 0.67 and right, F3,17 = 0.78,
P = 0.52; Table 2). Furthermore, there was no difference in
Table 1
Means, standard errors, and t-test statistics for blood parameters of female white-tailed deer in Control and PZP-treated groups at Seneca Army Depot, Romulus,
New York, 2000
Blood parameter Control group PZP group t-Test P-value
Sodium (mEq/L) 141.00 ± 1.48 141.21 ± 1.33 t = 0.09 P = 0.93
Potassium (mEq/L) 11.77 ± 0.97 11.14 ± 1.01 t = 0.37 P = 0.72
Chloride (mEq/L) 103.50 ± 2.11 101.21 ± 1.04 t = 1.09 P = 0.29
Bicarbonate (mEq/L) 23.00 ± 2.21 23.57 ± 0.74 t = 0.32 P = 0.75
Anion gap (mEq/L) 26.33 ± 4.18 27.64 ± 1.56 t = 0.37 P = 0.72
Urea-N (mg/dL) 8.00 ± 1.51 13.14 ± 1.19 t = 2.48 P = 0.02
Creat-rb (mg/dL) 1.27 ± 0.12 1.72 ± 0.10 t = 2.53 P = 0.02
Calcium (mg/dL) 9.75 ± 0.21 9.41 ± 0.24 t = 0.86 P = 0.40
Phosphate (mg/dL) 8.75 ± 1.11 8.70 ± 0.68 t = 0.04 P = 0.97
Magnes-xb (mg/dL) 2.55 ± 0.09 2.69 ± 0.12 t = 0.69 P = 0.50
TotProt (g/dL) 6.32 ± 0.36 6.56 ± 0.20 t = 0.63 P = 0.54
Alb-blk (g/dL) 3.13 ± 0.14 3.13 ± 0.05 t = 0.04 P = 0.97
Globulin (g/dL) 3.18 ± 0.22 3.43 ± 0.19 t = 0.74 P = 0.47
A/G 1.00 ± 0.04 0.95 ± 0.05 t = 0.56 P = 0.58
Glucose (mg/dL) 186.00 ± 82.08 149.86 ± 25.85 t = 0.55 P = 0.59
AST/PST (U/cL) 11.47 ± 5.29 31.53 ± 13.22 t = 0.97 P = 0.35
SDH (U/L) 67.18 ± 13.56 125.58 ± 47.91 t = 0.78 P = 0.45
Alk Phos (U/L) 197.87 ± 132.52 83.71 ± 10.44 t = 1.34 P = 0.20
GGT (U/L) 45.33 ± 2.80 56.14 ± 3.94 t = 1.70 P = 0.11
Tot Bili (mg/dL) 0.17 ± 0.02 0.26 ± 0.05 t = 1.33 P = 0.20
Dir Bili (mg/dL) 0.05 ± 0.03 0.13 ± 0.04 t = 1.32 P = 0.21
Ind Billi (mg/dL) 0.12 ± 0.03 0.12 ± 0.02 t = 0.03 P = 0.97
CK (U/cL) 130.10 ± 66.44 459.32 ± 200.61 t = 1.05 P = 0.31
Iron (g/dL) 155.67 ± 18.30 182.64 ± 13.38 t = 1.14 P = 0.27
Tibc (g/dL) 318.67 ± 28.24 342.00 ± 26.42 t = 0.52 P = 0.61
Sat (%) 48.50 ± 3.18 79.93 ± 28.11 t = 0.72 P = 0.48
Lipemia 32.50 ± 8.48 24.57 ± 5.82 t = 0.76 P = 0.46
Hemolysis 103.83 ± 34.68 196.14 ± 71.17 t = 0.82 P = 0.42
Note: A Bonferroni-corrected (n = 28 tests) alpha level of 0.05 is 0.002.
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Table 2
Weights (mg) of left and right ovaries, PZP antibody titers and incidence of oophoritis for control and PZP treated female white-tailed deer at Seneca Army
Depot, Romulus, New York, 2000
ID Treatment group LT ovary (mg) RT ovary (mg) Titer (1/Titer × 1000) Oophoritis
19 Control 573 606 0 N
21 Control 512 768 0 N
84 Control 507 324 0 NS
98 Control 689 523 0 N
148 Control 503 491 0 N
323 Control 408 306 0 N
378 Control 325 462 0 N
Means 502.4 497.1
144 1998 870 725 32,000 Y
146 1998 408 476 16,000 N
157 1998 922 1117 64,000 Y
159 1998 362 372 128,000 Y
178 1998 1152 1130 64,000 Y
180 1998 536 545 64,000 Y
182 1998 299 437 16,000 Y
188 1998 451 480 32,000 N
Means 625.0 660.2 52,000
With eosinophils
107 2000 819 601 NS N
109 2000 428 435 >128,000 N
142 2000 367 464 >128,000 N
Means 538.0 500.0
Without eosinophils
1 2000 451 669 128,000 Y
55 2000 464 430 128,000 Y
122 2000 477 605 >128,000 Y
Mean 464.0 568.0
Total 2000 mean 501.0 534.0
gross ovarian weights between the 2000 revaccinated deer
with and without oophoritis (P = 0.70 left and P = 0.71 right).
3.7. Oophoritis
Eosinophilic oophoritis was frequently observed in atretic
follicles of PZP-vaccinated females, and only seen in one soli-
tary follicle from a control female. Among 1998 vaccinates
6 of 8 females (75%) had follicular infiltrates, and among
2000 revaccinates, 3 of 6 (50%) showed similar follicular
infiltration (Table 3).
3.8. Follicle counts
There was no obvious trend or difference among the mean
count of Graafian follicles between treatments (F2,18 = 0.68,
P = 0.52). The only significant difference observed was a
lower average number of normal secondary follicles for the
deer revaccinated in 2000 when compared to the control
females (P = 0.04) and 1998 vaccinates (P = 0.04; Table 3).
When the 2000 revaccinate group was subdivided into those
deer exhibiting oophoritis and those without oophoritis, only
the group without oophoritis had significant reduction in the
number of normal secondary follicles compared to the con-
trols (P = 0.03) and the 1998 treatment group (P = 0.04). The
presence or absence of oophoritis among 2000 vaccinates
did not correlate with ovarian weight, nor the total number
of normal follicles per ovary.
3.9. Parasites and multifocal lymphocytic infiltrates
One deer was found with meningeal worms (Parelaphos-
trongylus tenuis; no. 178, 1998 treatment group), and two had
hepatic cysticerci (most likely Echinococcus granulosus; no.
55, 2000 treatment group, and no. 378, control group). These
animals were in good to excellent body condition. Focal infil-
trates and non-giant cell granulomas were seen in kidney,
skeletal muscle, and liver. These lesions were consistent with
immune attack against migrating parasites in tissues.
4. Discussion
4.1. Depleted bone marrow fat
Reduced fat content of bone marrow in PZP-treated deer
was first observed by pathologists at the Cornell University
College of Veterinary Medicine while conducting a necropsy
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Table 3
Ovarian follicle development for control and PZP-treated female white-tailed deer at Seneca Army Depot, Romulus, New York, 2000
Treatment Secondary follicles Graffian follicles Eosinophilic oophoritis Hyaline arteries
ID Group Normal Atretic % Atretic Normal Atretic % Atretic
19 Control 8 8 50 3 1 25 No Yes
21 Control 16 1 5 1 4 80 No Yes
84 Control 9 14 60 0 0 – Yes 1 follicle Yes
98 Control 11 13 54 0 3 100 No Yes
148 Control 6 17 73 0 1 100 No No
323 Control 4 8 66 0 1 100 No No
378 Control 3 11 78 0 1 100 No Yes
Means 8.1 10.3 55 0.6 1.6 72 1/7 5/7
144 1998 18 34 65 0 1 100 Yes No
146 1998 10 15 60 1 4 80 No No
157 1998 6 16 72 0 4 100 Yes Yes
159 1998 2 6 60 0 1 100 Yes Yes
178 1998 5 17 79 1 4 80 Yes Yes
180 1998 13 13 50 2 0 0 Yes Yes
182 1998 1 6 66 1 3 75 Yes Yes
188 1998 7 10 58 1 1 50 No Yes
Means 7.8 14.6 63.8 0.8 2.3 73.1 6/8 6/8
Without eosinophils
107 2000 2 12 85 1 4 80 Yes No
109 2000 8 20 71 0 1 100 Yes No
142 2000 2 6 75 1 2 66 Yes Yes
Means 4 12.7 77 0.7 2.3 82 3/3 1/3
Without eosinophils
1 2000 1 6 88 0 2 100 No Yes
55 2000 0 7 100 0 0 – No Yes
122 2000 1 8 88 0 1 100 No Yes
Means 0.7 7.0 92 0 1 100 0/3 3/3
Means revaccinates 2.3 9.8 84.5 0.3 1.7 89.2 3/6 4/6
on a single PZP-vaccinated deer from Irondequoit, New York
[26]. The total sample of treated deer examined was small,
and these results were not published.
Bone marrow fat is normally the last energy reserve used
in severe cases of malnutrition during winter [25,27]. Even
fawns confined to a restricted energy diet for 10 weeks during
the fall showed no significant difference in reserves of bone
marrow fat compared to fawns offered feed ad libitum during
the same time period [28,29]. Therefore, it is very unusual
to see marrow fat depleted while the deer are otherwise in
good to excellent body condition. The small number of PZP-
treated deer examined to date makes it difficult to isolate a
possible cause. Poor marrow fat content was also observed in
one control deer, further complicating possible explanations.
Additional investigation of the frequency and possible causes
for marrow fat depletion should be conducted, considering
that all cellular elements of blood develop from hematopic
stem cells in the bone marrow, including leukocytes, and T
and B lymphocytes of the adaptive immune system [30].
4.2. Injection site and other abscesses
A variety of infectious, parasitic, and non-inflammatory
lesions were described in these deer. Most remarkable was
the formation of granulomas at the injection site with all the
characteristics of tuberculosis. These granulomas were char-
acterized by the presence of a necrotic core surrounded by
mixed inflammatory cells and fibrous connective tissue. All
granulomas had Langerhans giant cells typical of tuberculo-
sis. Likewise, giant cell inflammation was seen in the regional
(popliteal) and deep (internal iliac) lymph nodes draining
these sites. Typical acid fast bacilli were documented in these
giant cells and were still apparent in the lesions and lymph
nodes 2 years following injections. These types of inflamma-
tions, including the production of multinucleated giant cells
associated with the presence of Mycobacteria in the adjuvant,
have been previously described in other species vaccinated
with Freund’s Complete Adjuvant [19,31–34].
4.3. Lactation
Residual milk, in even a completely involuted udder, is
considered evidence that a doe had raised fawns during the
previous summer [35,36]. Our findings corroborated the Cur-
tis et al. [7] report that five PZP-vaccinated deer delivered
fawns in 2000. The fact that none of the six deer revaccinated
in 2000 had lactated was a result of the selection of deer
receiving the revaccination, not the treatment itself. The lac-
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tation evidence further confirms the return to normal fertility
for PZP-vaccinated deer, even as some continue exhibiting
oophoritis.
4.4. Histological findings
Ovarian inflammation resulting from PZP immunocontra-
ceptive vaccinations have been extensively studied for many
species [9–11,13,14,16–18,37–39]. However this is the first
report of eosinophilic oophoritis in ovaries from PZP-treated
white-tailed deer. We documented both B-cell humoral and
T-cell response from the same injection formula, and we were
also able identify reproductive recovery in deer still experi-
encing eosinophilic oophoritis. The two most striking results
from the necropsied deer were: (1) the widespread docu-
mentation of eosinophilic oophoritis in PZP-vaccinated deer,
and (2) the reduced number of normal secondary follicles in
females without oophoritis that were revaccinated in 2000.
Oophoritic inflammation of the ovary, in our study, specif-
ically describes the infiltration of eosinophils (and to lesser
extent neutrophils) into the theca interna across the base-
ment membrane, and into the cumulus oophorus, or zona
granulosa layer. However, it appears that apoptosis (a hall-
mark of follicular atresia) is necessary before eosinophils
progress through the theca interna. Eosinophils were never
seen within the lumen of the follicle until the glassy mem-
brane was first formed. Also, this inflammation was restricted
to secondary and Graafian follicles; which was particularly
interesting because the oocytes of the primary follicles were
likewise surrounded by the zona pellucida (ZP). Multifocal
aggregates of small lymphocytes were also commonly seen
in the ovarian parenchyma (but not in the follicles). Although
ovaries are not considered to provide a distinct morphologic
barrier from the immune system [18,40], it appeared that
the ZP was protected by the ovary from eosinophilic attack
until ovulation or atresia. This supports the observations by
McShea et al. [4] who noted neutrophils in atretic follicles,
but not eosinophils.
In humans, eosinophils are inflammatory cells which
develop in the bone marrow under the influence of sev-
eral T-lymphocyte produced cytokines (IL-3, IL-5) [41,42].
They are activated by platelet-activating factor and the
split products of the complement system (C5a, C3a, C4a)
[43–45]. These eosinophils then migrate to sites of inflam-
mation within specific tissues under the influence of various
chemokines including eotaxin 1–3 (CCL11, CCL 24, CCL
26) secreted by fibroblasts [41,46,47]. At the site of inflam-
mation, eosinophils release cationic and basic proteins,
or reactive oxygen species, which leads to cellular death
and simultaneous release of various chemokines, includ-
ing MIP-1a (CCL3), RANTES (CCL5), and IL-8 (CXCL8)
[41,48,49]. Thus eosinophils, in addition to an effector
function, control their own accumulation as well as the
recruitment of other leukocytes such as T cells, monocytes,
neutrophils, and basophils [42]. Observations made on deer
in this study indicated that ovarian ZP antigens presented to
the immune system stimulated release of chemokines, which
attracted eosinophils. The eosinophils then modulated the
subsequent inflammatory response in the ovary.
We observed that 2000 PZP revaccinates had the great-
est reduction in secondary follicles for those deer that
lacked eosinophilic infiltration. This is best explained by an
antibody-mediated attack against the ZP antigens, resulting
in complement-mediated destruction, where T-helper cells
secreted IL-4 and IL-10, enhanced B-cell production of anti-
bodies, and interfered with the T-cell production of cytokines
necessary for an inflammatory response. Thus, cellular events
occurring within the ovary following PZP vaccination set
the stage for primarily antibody-mediated activity, or cellular
inflammation, but not both at the same time [30].
The observation that the eosinophils only occurred during
atresia signified that oophoritis is not a sign of impeded ovar-
ian function, but rather indicative of normal ovulation. Such
an observation could be expected in successful contraception
of deer when females display typical cyclic behavior. The
question then would be: does the oophoritis cause pain or
distress to the deer? Observations of good to excellent body
condition for most deer in our study would imply that they
were not impaired by PZP vaccination.
Conversely, half of the 2000 PZP revaccinates had signif-
icantly fewer normal secondary follicles and no eosinophilic
invasion. Such follicular deterioration has been associ-
ated with inhibited ovarian function, abnormal cycling, or
suppressed progesterone levels observed in many species
[9,11,14,16,18,38].
4.5. Anomalies
As for any species, reproductive anomalies can arise.
A small number of women experience infertility due to
premature ovarian failure from autoimmune oophoritis dis-
tinguished by ovarian lymphocyte infiltrates [17,18,50].
Similarly, we identified a control female (deer no. 84)
maintained in the same environment with exposure to repro-
ductively active males similar to other female deer on trial, yet
failed to produce fawns during the course of the field study.
The human case described by Page et al. [50] was deter-
mined to be eosinophilic perifolliculitis and tested positive
for serum antiovarian antibodies. Similar to the human case,
this infertile doe had an eosinophilic infiltrate in one of her
ovaries without any treatment or sham injection, indicating
self-induced autoimmune activity.
It is noteworthy that deer number 159 maintained a titer
of 1:128,000 2 years post-vaccination, and had no injection
site lesions. Miller et al. [15] observed similar prolonged
immunocontraceptive efficacy and high titers, indicating the
potential for continued self-inoculation each fall as normal
ovulation resumed. Miller et al. [51] offered that variations
in the residual immune response and physiological, morpho-
logical, or pathological differences among deer receiving
identical treatments are likely due to genetic differences
among individual animals from the same population.
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5. Summary
Many factors affect the success and potential pathology
associated with an immunocontraceptive vaccine, including
formulation of the immunogen, concentration of the immuno-
gen, adjuvant used, and species treated. Therefore, before
judgments can be made concerning the effectiveness and
health risks associated with a given vaccine for a particular
species, adequate evaluation must be conducted.
Deer vaccinated with PZP in this study continued to
exhibit eosinophilic oophoritis 2 years after the last booster
injection, including some deer that had already returned to
normal fertility. The long-term health implications resulting
from the Curtis et al. [7] vaccination protocol and asso-
ciated pathologies are still unknown, and further study is
advisable.
Observation of deer with bone marrow fat depletion, at a
time of year when they should have their maximum energy
reserves prior to winter, is an important concern. In climates
with severe winters and deep snow, deer exhibiting reduced
bone marrow fat during late summer and fall could be at
risk for malnutrition and death if harsh conditions are pro-
longed. Hence, regardless of any possible connection to the
PZP vaccine, continued effort to find the cause and extent
of this condition should be a research priority, especially for
deer herds in northern climates.
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